

Boehringer Ingelheim has established its reputation with a successful market introduction of 15 DNA-derived biopharmaceutical products. Four of these products are among the top 20 of the worldwide selling list. We continuously move ahead advancing with the benefit of our own research, through collaboration with research-oriented companies and our commercial partners, and working with leading academic networks.